Navigation Links
Illinois Pharmaceutical Manufacturer Sued for Injuries to Kentucky Resident
Date:5/14/2008

Injuries Believed to be Caused by Contaminated Blood Thinner

CHICAGO, May 14 /PRNewswire/ -- The blood thinner Heparin continues to make headlines as more people are found to have suffered serious injuries and/or death after using the contaminated drug -- a group of which appears to include many Kentucky residents. On Friday, May 2, 2008, another lawsuit was filed against Chicago-area pharmaceutical giant, Baxter International Inc. on behalf of Louisville, Kentucky resident, Artemus Banks. The complaint was filed by Nolan Law Group in Federal Court located in Chicago, Illinois. Nolan Law Group has already been responsible for filing several lawsuits on behalf of victims and the families of victims who have suffered a personal injury and/or death caused by the use of this contaminated drug. Due to the enormity and severity of the contamination, Nolan Law Group expects to file many more similar cases.

This most recent lawsuit names Scientific Protein Laboratories L.L.C. (the company which manufactures the active pharmaceutical ingredient API in Heparin) as well as certain corporate officers of Baxter. The lawsuit asserts that Baxter International and its wholly-owned subsidiary, Baxter Healthcare Corporation, manufactured the drug with a contaminated API and that Baxter failed to recall the defective drug in a timely fashion. The suit cites four causes of action against Baxter and Scientific Protein Labs including Products Liability, Negligence, Breach of Warranties and Willful and Wanton Misconduct.

Baxter's Heparin has been implicated in more than 400 life-threatening incidents and may be responsible for as many as 81 deaths. In February 2008, Baxter initiated a voluntary recall of nine lots of Heparin Sodium Injection Multi-Dose Vials. According to Baxter International, they recalled the lots due to a spike in adverse reports associated with the use of Baxter Heparin Sodium Injections. After receiving additional reports of similar ad
'/>"/>

SOURCE Nolan Law Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cytochroma opens U.S. headquarters in Illinois
2. Meredith Martin Addy Named One of Top 10 Illinois Super Lawyers for 2008
3. Twenty-One Brinks Hofer Gilson & Lione Attorneys Named 2008 Illinois Super Lawyers
4. Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
5. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
6. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
8. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
9. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
10. Medimetriks Pharmaceuticals, Inc. Begins Operations
11. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Research and Markets has announced the ... Instruments Market 2014-2018" report to their offering. ... is the study of the gene and its functions ... functions of proteomes or sets of proteins by using ... the mapping of genes and DNA sequencing to understand ...
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... 24, 2014  Neogen Corporation (Nasdaq: NEOG ... its potential revenue from new rodenticide research are premature. ... analysts on July 22, 2014, Neogen,s CEO commented about ... research. "It was my intent Tuesday at ... of a new type of rodenticide, but certainly not ...
(Date:7/24/2014)... Toronto, Canada (PRWEB) July 24, 2014 ... for Optimizing Dose Escalation in First in Human Studies” ... to make better go/no-go decisions. , With increasing R&D ... market, pharmaceutical companies need to maximize the knowledge collected ... go/no-go decisions and improve success in late stage development. ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... workforce reduction, NEW YORK, April 4, 2008 ... that it is implementing a,strategic restructuring plan to ... efforts. The plan, which was prompted by the ... clinical trial of Sulonex(TM),(sulodexide) for the treatment of ...
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), a ... that the first New Zealand patient,was treated with ... December 2007. A second patient was treated in ... drug-eluting stent for peripheral,arterial disease (PAD) and was ...
... held at the Society for Biomolecular Sciences 14th ... ... Ltd., an,international provider of microfluidic systems in the emerging field of,nano-lifesciences, ... enables researchers to execute physiologically,relevant flow experiments evaluating the adhesion of ...
Cached Biology Technology:Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 2Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 3Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 4Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 3Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 4Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays 2
(Date:7/25/2014)... time, Spanish researchers have detected an unknown interaction between ... are introduced into a droplet of salt water and ... crystallisation to create biomineralogical biosaline 3D morphologically complex formations, ... bacteria are revived. The discovery was made by chance ... of the Astrobiology journal and may help ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... numbers have decreased by 45% on average over a ... reports a study on the impact of humans on ... enormous benefits invertebrates such as insects, spiders, crustaceans, slugs ... and pest control for crops, decomposition for nutrient cycling, ... in Science and led by UCL, Stanford ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... abnormalities like hypertension, obesity, insulin resistance, and excess ... disease and diabetes. Individuals with a genetic predisposition ... be especially vulnerable to metabolic syndrome, but researchers ... desaturase-1 (SCD1), which helps synthesize unsaturated fatty acids, ...
... have identified the gene that sets off a sequence ... adults that can lead to high blood pressure. The ... the creation of blockages that can cause heart attacks, ... a study led by Ohio State University researchers might ...
... the western world, but new therapies based on stem cells ... held back however by the difficulty testing new therapies on ... value owing to differences in structure and activity. The only ... create computerised in-silico models that simulate the real heart and ...
Cached Biology News:High blood pressure in older adults traced to gene's effects in blood vessels 2High blood pressure in older adults traced to gene's effects in blood vessels 3The construction of heart modelling leads path to new therapies 2The construction of heart modelling leads path to new therapies 3
... 1;heading 2;Many mammalian ... experimental situations create ... transfection and other ... ViraPower Lentiviral Expression ...
... Rabbit polyclonal to Kv4.2 Immunogen ... corresponding to amino acids 23-43 of Rat ... with Rat.Expected to cross-react with Human (100% ... immunogen), Rabbit (100% identity with immunogen) and ...
RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... Cryo/CryoPlus Inventory Racks for ... available with cardboard or stainless ... or 5ml cryo vials. ... racks available. Platform risers ...
Biology Products: